- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05676242
Et fase III udvidet klinisk forsøg med Jaktinib Hydrochloride-tabletter til behandling af moderat og svær atopisk dermatitis
Et fase III udvidet klinisk forsøg med langsigtet sikkerhed og effektivitet af Jaktinib Hydrochloride-tabletter til behandling af moderat og svær atopisk dermatitis
To observe the safety and effectiveness of long-term use of jaktinib hydrochloride tablets in the treatment of moderate and severe atopic dermatitis
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
If the enrolled subjects received the treatment of jaktinib hydrochloride tablets in the ZGJAK025 trial, they will continue to use the drug at the original dosage; If the enrolled subjects received placebo treatment in the ZGJAK025 trial, they will receive 100mg BID of jaktinib hydrochloride tablets, 75mg BID of jaktinib hydrochloride tablets or placebo at a ratio of 1:1:1 at random, and continue to take the drug on an empty stomach, with the longest continuous treatment not exceeding 36 weeks.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100044
- Peking University People's Hospital
-
-
Jiangsu
-
Nanjin, Jiangsu, Kina
- Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences, Peking Union Medical College
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- The investigator thinks that the subject can continue to benefit from participating in the extension trial;
- Fully understand the extension trial and sign the informed consent form;
- Complete the ZGJAK025 trial for 16 weeks and have good compliance;
- It is expected that the time interval between the first administration and the last administration of ZGJAK025 trial for the subject should be ≤ 4 weeks;
Exclusion Criteria:
- Within 4 weeks before enrollment, there were any adverse events ≥ 3 levels related to the test drug that did not return to level 1 or normal;
- The investigator thinks that the subject is not suitable for the trial.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Jaktinib 100mg BID
Drug: Jaktinib Hydrochloride Tablet 100mg dosage, orally administered, twice a day |
Orally administered, twice a day |
|
Eksperimentel: Jaktinib 75mg BID
Drug: Jaktinib Hydrochloride Tablet 75mg dosage, orally administered, twice a day |
Orally administered, twice a day |
|
Placebo komparator: Placebo
Drug: Placebo Orally administered, twice a day |
Orally administered, twice a day |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number and percentage of subjects with treatment emergent adverse event (TEAE)
Tidsramme: 36 weeks after the first dose
|
Safety of the drug |
36 weeks after the first dose
|
|
Number and percentage of subjects with Serious Adverse Event (SAE)
Tidsramme: 36 weeks after the first dose
|
Safety of the drug |
36 weeks after the first dose
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The diachronic change in the proportion of subjects whose total Eczema area and severity index (EASI) score decreased by ≥ 75% from baseline
Tidsramme: 36 weeks after the first dose
|
The proportion of subjects who reached EASI-75 |
36 weeks after the first dose
|
|
The diachronic change of the proportion of subjects whose systemic Investigator's Global Assessment (IGA) score reached 0 or 1 and decreased by ≥ 2 points from baseline
Tidsramme: 36 weeks after the first dose
|
The proportion of subjects who reached IGA 0/1 |
36 weeks after the first dose
|
|
The diachronic change in the proportion of subjects whose pruritus Numerical Rating Scale (NRS) score improved by ≥ 4 points from baseline
Tidsramme: 36 weeks after the first dose
|
The proportion of subjects who reached NRS4 |
36 weeks after the first dose
|
Samarbejdspartnere og efterforskere
Efterforskere
- Studiestol: Jason Wu, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- ZGJAK026
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .